[1] Bertuccio P, Turati F, Carioli G, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol, 2017, 67:302-309. [2] Elserag H B, Marrero J A, Rudolph L, et al. Diagnosis and treatment of hepatocellular carcinoma.Gastroenterology, 2008, 134:1752-1763. [3] Tzartzeva K, Obi J, Rich N E, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: A meta-analysis. Gastroenterology, 2018, 154:1706-1718. [4] 王志亮, 逄越, 李庆伟. 白细胞衍生趋化因子2及其受体介导的信号通路与疾病. 中国生物化学与分子生物学报, 2017, 33:879-885. [5] Okabe H, Delgado E, Lee J M, et al. Role of leukocyte cell-derived chemotaxin 2 as a biomarker in hepatocellular carci-noma. PloS One, 2014, 9:e98817. [6] Llovet J M, Bisceglie A M D, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst, 2008, 100:698-711. [7] 王贵强, 王福生, 成军,等. 慢性乙型肝炎防治指南(2015年更新版). 中国病毒病杂志, 2015, 31:1941-1960. [8] 科技部十二五重大专项联合课题组. 乙型肝炎病毒相关肝硬化的临床诊断、评估和抗病毒治疗的综合管理. 中华消化杂志, 2014, 30:138-148. [9] Chen CK, Yang CY, Hua KT, et al. Leukocyte cell-derived chemotaxin 2 antagonizes MET receptor activation to suppress hepatocellular carcinoma vascular invasion by protein tyrosine phosphatase 1B recruitment. Hepatology, 2014, 59:974-985. [10] Chen CK, Yu WH, Cheng TY, et al. Inhibition of VEGF165/VEGFR2-dependent signaling by LECT2 suppresses hepato-cellular carcinoma angiogenesis. Sci Rep, 2016, 6:31398. |